Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Pioglitazone on Inflammatory Response and Clinical Outcome in T2DM Patients With COVID-19

NCT04604223 is registered in ClinicalTrials.gov with Dasman Diabetes Institute as lead sponsor.

NCT NCT04604223
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04604223 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Pioglitazone on Inflammatory Response and Clinical Outcome in T2DM Patients With COVID-19
Lead sponsor
Dasman Diabetes Institute
Phase
Phase 4
Overall status
Unknown status
Start date
January 18, 2021
Completion date
June 29, 2021
Enrollment
1,506 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

covid19, type 2 diabetes